NCT07459296 2026-03-16
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Phase 3 Recruiting
Clinical Trials
10 trialsNCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT05549037 2025-02-19
PACIFIC15
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT05495152 2024-10-02
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3 Recruiting
NCT05918094 2024-01-26
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT05608200 2023-05-31
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 3 Recruiting
NCT05236972 2022-12-30
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Phase 3 Recruiting